IP Verse

Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)

Patent No. EP3858859 (titled "Method Of Treating Cancer Using Immune Checkpoint Inhibitor; Antibody That Binds To Programmed Death-1 Receptor (Pd-1) Or Programmed Death Ligand 1 (Pd-L1)") was filed by Bristol Myers Squibb on Jul 14, 2016. The application was issued on Oct 29, 2025.

Patent Summary

Nivolumab is used as a monotherapy for treating subjects with recurrent or metastatic human papillomavirus (HPV) positive squamous cell carcinoma of the head and neck (SCCHN). The method comprises administering a therapeutically effective amount of nivolumab, an anti-PD-1 antibody, to a subject in need thereof. HPV positivity may be identified by measuring HPV levels in a subject sample, including identifying nucleotide sequences or proteins such as p16, Ki-67, Cyclin D1, p53, ProEx C, E6, or E7, or via p16 immunohistochemistry showing strong and diffuse nuclear and cytoplasmic staining in over 50% to 70% of tumor cells. The therapy aims to increase progression-free survival and overall response rates compared to standard-of-care treatments.

Patent Family

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STORZJul 29, 2026-
BRAND MURRAY FULLERJul 28, 2026BRAND MURRAY FULLER
DEVA HOLDINGJul 28, 2026-
MAIWALD PATENTANWALTSJul 28, 2026MAIWALD PATENT- UND RECHTSANWALTSGESELLSCHAFT MBH
PAJAROJul 28, 2026BIRD & BIRD
GREINERJul 27, 2026GREINER
POHLMANJul 17, 2026PAGE
MANZERJul 13, 2026TER MEER STEINMEISTER & PARTNER GBR
MANZERJul 13, 2026TER MEER UND PARTNER
WUESTHOFF & WUESTHOFFMar 12, 2026WICHMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3858859

BRISTOL MYERS SQUIBB
Application Number
EP20214749A
Filing Date
Jul 14, 2016
Status
Granted And Under Opposition
Sep 26, 2025
Publication Date
Oct 29, 2025
External Links
Slate, Register , Google Patents